News Releases
Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
Feb 18, 2021- Submissions will be Reviewed Under Real-Time Oncology Review Based on Clinical Trials EV-301 and Cohort 2 of EV-201 -
-
Feb 12, 2021- Durable Tumor Responses Experienced Among Patients Previously Treated with Immunotherapy in Second Cohort of EV-201 Trial -
-
Feb 12, 2021- Findings from the EV-301 Trial Showed Significant Improvements in Overall Survival and Progression-Free Survival Compared to Chemotherapy -
-
Feb 4, 2021Oncology head Mark Reisenauer named Astellas US President; Masahide Goto named President at Astellas Institute for Regenerative Medicine
-
Feb 3, 2021- Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings
-
Dec 14, 2020Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise